NuGEN Granted Patent for RNA Amplification Technology
News Sep 21, 2005
NuGEN Technologies, Inc. has announced that the United States Patent and Trademark Office issued U.S. Patent No. 6,946,251 entitled, "Methods and Compositions for Amplification of RNA Sequences."
This patent establishes protection around the company's innovative linear, isothermal RNA amplification technology which has widespread applications in life science research, therapeutic and diagnostics.
The patent covers methods, applications and kits, and provides protection for NuGEN's Ribo-SPIA™ methods and reagents that power NuGEN's Ovation™ family of products.
The Ovation™ System is designed to provide methods and reagents for both 3' based RNA amplification and whole transcriptome amplification.
Unlike the commonly used RNA amplification methods that are based on in vitro transcription, Ribo-SPIA™ is a single round amplification that is designed to provide efficient amplification to generate microgram amounts of cDNA products from minute (nanogram level and lower) amounts of total RNA.
NuGEN's isothermal nucleic acid amplification technologies are protected by a number of U.S. and foreign issued patents and patent applications.
Unlike most cells in the rest of our body, the DNA (the genome) in each of our brain cells varies from cell to cell, caused by somatic changes. But much remains unknown, including when these changes arise, their size and locations, and whether they are random or regulated. Now, researchers have developed new techniques allowing the detection of CNVs smaller than one million base pairs.